0001144204-12-054936.txt : 20121214 0001144204-12-054936.hdr.sgml : 20121214 20121005155700 ACCESSION NUMBER: 0001144204-12-054936 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20121005 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NOVAVAX INC CENTRAL INDEX KEY: 0001000694 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 222816046 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 9920 BELWARD CAMPUS DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 240-268-2000 MAIL ADDRESS: STREET 1: 9920 BELWARD CAMPUS DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 CORRESP 1 filename1.htm

VIA EDGAR

October 5, 2012

Securities and Exchange Commission

Division of Corporate Finance

100 F Street, N.E.

Washington, D.C. 20549-7010

Attention:

Mary Mast

Vanessa Robertson

Joel Parker

Jim Rosenberg

Re:

SEC Comment Letter dated August 9, 2012

Novavax, Inc.

Form 10-K for the year ended December 31, 2011

Filed on March 14, 2012

Form 10-Q for the quarterly period ended March 31, 2012

Filed on May 9, 2012

File No. 000-26770

Ladies and Gentlemen:

On behalf of Novavax, Inc. (the “Company”), this letter is to confirm our receipt of the SEC’s oral comments during my telephone conversation with Ms. Robertson of the staff of the Securities and Exchange Commission on October 2, 2012. I have advised Ms. Robertson that our response to these oral comments letter would be provided by October 31, 2012.

Very truly yours,

/s/ John A. Herrmann III

John A. Herrmann III

Vice President, General Counsel & Corporate Secretary